We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boehringer Ingelheim Partners With Ribo in $2B Deal to Develop Liver Therapies
Boehringer Ingelheim Partners With Ribo in $2B Deal to Develop Liver Therapies
Suzhou Ribo Life Science and Ribocure Pharmaceuticals (Ribo) announced a $2 billion collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
